A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: H1N1 influenza A Vaccine (Split virion), Inactivated
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT01004653
- Locations
- 🇨🇳
Beijing Centers for Diseases Control and Prevention, Beijing, China
A Clinical Trial With Influenza A/H1N1 Vaccines
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: placebo controlBiological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per doseBiological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per doseBiological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per doseBiological: split-virion, adjuvanted H1N1 vaccine of 15 μg per doseBiological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per doseBiological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 1614
- Registration Number
- NCT00956111
- Locations
- 🇨🇳
Beijing Centers for Diseases Control and Prevention, Beijing, China
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Registration Number
- NCT00900588
- Locations
- 🇨🇳
Beijing Centers for Diseases Control and Prevention, Beijing, China
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Registration Number
- NCT00900991
- Locations
- 🇨🇳
Beijing Centers for Diseases Control and Prevention, Beijing, China
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
Phase 1
Completed
- Conditions
- Pandemic Influenza VaccinePreventionPandemic Influenza
- Interventions
- Biological: pandemic influenza vaccine (H5N1 strain NIBRG-14)
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 57
- Registration Number
- NCT00660257
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
Phase IV Clinical Trial of an Influenza Split Vaccine Anflu
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: seasonal split influenza vaccine
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 566
- Registration Number
- NCT00556062
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
Phase 2
Completed
- Conditions
- Pandemic InfluenzaPrevention
- Interventions
- Biological: pandemic influenza vaccine (H5N1 strain NIBRG-14)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 402
- Registration Number
- NCT00535665
Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine
Phase 4
Completed
- Conditions
- Hepatitis A
- Interventions
- Biological: Healive® Lot 1Biological: Healive® Lot 2Biological: Healive® Lot 3Biological: Havrix
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT00534885
- Locations
- 🇨🇳
Changzhou City Center for Disease Control and Prevention, Changzhou, Jiangsu, China
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- Sinovac Biotech Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT00356798
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath